About Us
PRISME Forum
In 2011, two pioneering organizations—PRISM and PRIME—joined forces to form the PRISME Forum. This union was born out of a shared vision to foster collaboration, innovation, and excellence within the pharmaceutical and life sciences industries. By combining their strengths and expertise, PRISM and PRIME created a platform that has since become a cornerstone for knowledge exchange and strategic partnerships. The PRISME Forum stands as a testament to the power of unity, bringing together the best of both worlds to drive forward our collective mission.
PRISME Forum is devoted to improvement of general business conditions in the biotech and pharma industry and will not provide any services that would normally be carried out for profit. PRISME Forum observes all relevant anti-trust requirements and will not facilitate or allow discussions regarding commercially sensitive or confidential information. PRISME Forum will not engage in any political or legislative activities.
Our Mission
The mission of the PRISME Forum will be to provide a forum for the exchange of non-commercially sensitive information among its members in order to enhance the efficiency, effectiveness and impact of global Research and Development Information Management and Information Technology (“R&D IT”) organizations within the biotechnology and pharmaceutical (“biotech and pharma”) industries.
PRISME Forum will be devoted to improvement of general business conditions in the biotech and pharma industries and will not provide any services that would normally be carried out for profit. PRISME Forum will observe all relevant anti-trust requirements and will not facilitate or allow discussions regarding commercially sensitive or confidential information. PRISME will not engage in any political or legislative activities.
Goals and Value
PRISME Forum Goals
1. Establish and maintain a network among the Members that fosters open communication of non-commercially sensitive information.
2. Educate Members regarding best practices in R&D IT in the biotech, pharma and other industries.
3. Promote the development and use of open standards for applications utilized in biotech and pharma R&D.
4. Create opportunities for open and informal dialogue between the Membership and suppliers of IT products used in biotech, pharma R&D and related life sciences organizations.
5. Alert Members to new and emerging information technologies and products of special relevance to biotech and pharma R&D.
6. Operate at all times within the statement of compliance.
Our Value…
… TO OUR MEMBERS
- External perspectives from trusted peers, “safe space” for advice
- Early insights in emerging trends, validation of industry-wide challenges
- Long-term professional networking
- Development opportunities for team members/ delegates
… TO THE INDUSTRY
- Well-connected leaders drive innovation
- Technical Meetings create high-quality interactions between innovators
- PRISME members are key influencers in other pre-competitive collaboration groups
PRISME Forum Board Chair
Mike Sullivan, MBA
Mike Sullivan, MBA, is Chair of the PRISME Forum Board and executive director, IT for Clinical Development at Bristol Myers Squibb, where he oversees IT operations within Clinical Development and leads the strategic partnership between IT and Global Development Operations.
Mike brings more than 25 years of experience with global organizations and a deep understanding of how technology creates value across the drug-development lifecycle.
As Chair, he guides the Board and works with PRISME Forum leadership to strengthen membership, deepen participation, and increase the practical value delivered to members.
He earned his MBA from Northeastern University and his bachelor’s degree in information systems analysis and development from Drexel University.
SENIOR ADVISOR TO THE BOARD
Amrik Mahal, PhD, BEM
Dr. Amrik Mahal, BEM, is chief operating officer for Life Sciences at Amino Data and senior strategic advisor to the PRISME Forum Board. In this non-voting role, he supports the Chair, executive director, and Board with strategic direction, membership development, senior-level introductions, programming, and the Forum’s continued relevance.
Previously, Amrik was global head of information technology for Research at AstraZeneca and head of IT for Sweden. His career spans pharmaceutical research, technology, and academia, including roles with Glaxo Wellcome, Oxford Asymmetry, and Evotec. He was awarded the British Empire Medal for his contributions to the United Kingdom’s COVID-19 response and to science.
EXECUTIVE DIRECTOR
Martin Erkens, PhD
Martin Erkens, PhD, recently retired from his role at Roche and, as of January 1, 2026, has begun serving as the Executive Director of the PRISME Forum. He previously served as Executive Lead of Pharma Research and Early Development Informatics (pREDi), where he oversaw data‑science initiatives supporting drug discovery and development, as well as the implementation of workflow solutions across research and early development.
Throughout his career at Roche, Dr. Erkens led multiple global programs across clinical and preclinical domains — including systems for drug project and portfolio planning, global sales reporting, electronic data capture for clinical trials (Roche’s first large‑scale cloud system), clinical imaging, and digital environments for early development. His organization also delivered foundational tools such as a research imaging data warehouse, omics laboratory LIMS, and data‑review platforms for early clinical studies.
Before heading pREDi, he managed several IT teams in the clinical space and played a key role in defining a new global system landscape for clinical development, driving modernization efforts that strengthened scientific workflows, data quality, and operational efficiency across the enterprise.
Dr. Erkens earned his PhD in Mathematics (stability theory) from Albert Ludwigs Universität, Freiburg, where he also completed degrees in Mathematics and Physics (“Diplom” and “Staatsexamen”).
BOARD OF DIRECTORS
Dan Chapman, PhD
Dan Chapman, PhD, is part of the leadership team within Informatics at UCB with responsibility for Software Development and Architecture and Therapeutic Informatics (UK).
Dr. Chapman has 15 years’ experience working within the Pharmaceutical industry in a variety of roles.
After completing a PhD in Chemistry at Warwick University, he transitioned to informatics during post-doctoral research at Cambridge University as part of the CLIC consortium. Dr. Chapman joined AstraZeneca in 1997 and worked on a variety of global projects before joining UCB in his present role in 2005.
Since then, he has driven several projects to revolutionize the informatics platform within UCB and is currently actively involved in promoting Data Science across UCB.
Dr. Chapman had served as the PRISME Forum Chair between 2018-2023.
Lars Greiffenberg, PhD
Lars Greiffenberg, PhD, MS, serves as Senior Director, R&D Information Research; Research Fellow; and Enterprise Knowledge Accelerator at AbbVie. He leads enterprise‑level initiatives to transform how scientific literature is accessed, consumed, and leveraged, and oversees a team applying modern computational methods and algorithms to extract and visualize mechanistic disease information from the scientific literature. His responsibilities also include global Library Sciences, which he assumed in 2017, and the Academic Partnerships Organization, added in 2018, which leverages an AbbVie–Campus collaboration at the University of Illinois Urbana–Champaign.
He joined AbbVie in 2014 in Ludwigshafen, Germany, as Director of R&D IT and Translational Informatics, heading business IT support across data and digital solutions from early discovery through Medical Affairs. Before AbbVie, he held multiple R&D IT leadership roles at Aventis Pharma and Sanofi‑Aventis in Frankfurt, later relocating to Toulouse as Global Head of Solution Center Translational Medicine, where he led a global program enabling translational science at Sanofi. Lars is also active in several pre‑competitive organizations, including IMI, PRISME Forum, Pistoia Alliance, and EIT‑Health.
He holds an MS in Biology and a PhD in Microbiology and has more than 15 years of experience in integrated R&D IT solutions and translational informatics.
Amrik Mahal, PhD, BEM
Previously, Amrik was global head of information technology for Research at AstraZeneca and head of IT for Sweden. His career spans pharmaceutical research, technology, and academia, including roles with Glaxo Wellcome, Oxford Asymmetry, and Evotec. He was awarded the British Empire Medal for his contributions to the United Kingdom’s COVID-19 response and to science.
Leah O'Brien
Leah is an enterprise leader with purpose, presence and agility, with extensive experience in broadening impact, building connections and developing organizations. She is passionate about the role that technology plays in labs to accelerate the delivery of life-changing treatments to patients.
Anthony Rowe, PhD
A specialist in computational biology, AI/ML, digital health, biosensors, and advanced analytics, he is known for bringing scientific depth together with product‑driven technology leadership. His work focuses on building modern research platforms, enabling multimodal data integration, and translating cutting‑edge computational methods into real impact for GSK’s discovery and translational programs. Anthony’s leadership reflects more than two decades of experience at the intersection of computing, life sciences, and large‑scale digital transformation.
Before joining GSK, Anthony spent over 14 years at Johnson & Johnson Innovative Medicine, rising to Vice President and Head of Technology for Research Systems, where he oversaw digital strategy and technology enablement for discovery, early development, and clinical supply. His earlier roles included leading global scientific information systems, data science initiatives, and AI‑driven research capabilities.
Anthony also serves on the Board of Directors of the Pistoia Alliance and previously contributed to Nature’s Scientific Data advisory panel, underscoring his commitment to open science and data standards. He holds both an MSc in Advanced Computing and a PhD in Computing from Imperial College London, where he specialized in artificial intelligence and computational methods.
Errol Sandler, PhD
Dr. Sandler provided leadership and technical expertise for Research & Development computing in the pharmaceutical industry. Most recently, he led teams to provide information technology support at several Pfizer Global research and development sites in the United States and the United Kingdom.
Dr. Sandler received his PhD in Physics and Astronomy in July of 1977 from the University of Missouri-Columbia.
Mike Sullivan, MBA
Mike brings more than 25 years of experience with global organizations and a deep understanding of how technology creates value across the drug-development lifecycle. As Chair, he guides the Board and works with PRISME Forum leadership to strengthen membership, deepen participation, and increase the practical value delivered to members. He earned his MBA from Northeastern University and his bachelor’s degree in information systems analysis and development from Drexel University.
Miguel Teodoro, PhD, MS
Miguel Teodoro, PhD, MS, is the global Head of IT Research, Translational Medicine, and Clinical Pharmacology at Boehringer Ingelheim. In this role, he defines and drives the global IT strategy for pharmaceutical research, aligning R&D priorities with digital, data, and analytics capabilities to measurably accelerate scientific decision‑making across the R&D value chain.
Miguel has more than two decades of experience at the intersection of life sciences and information technology. Since joining Boehringer Ingelheim, he has held a series of senior leadership positions within R&D IT, spanning discovery informatics, high‑performance computing, research platforms, and architecture. His work has focused on building scalable, sustainable digital platforms and data foundations that accelerate scientific innovation while ensuring robust governance and compliance in a global research environment.
He holds a PhD in Biochemistry and Computational Chemistry and an MS in Computer Science from Rice University, as well as a degree in Applied Chemistry/Biotechnology from Universidade Nova de Lisboa. This interdisciplinary background enables him to bridge scientific and technological perspectives and to lead multidisciplinary teams delivering advanced digital capabilities for R&D organizations.
As a member of the PRISME Forum Board of Directors, Miguel is committed to advancing pre‑competitive collaboration, sharing best practices, shaping industry approaches to R&D IT strategy, and adopting new technologies across the global biopharmaceutical community.